CLAIMS

1. Film-shaped, mucoadhesive administration form containing a cannabis extract or a cannabis oil.

2. Administration form according to claim 1, characterized in that it has a polymer matrix which serves as active substance reservoir and has mucoadhesive properties.

3. Administration form according to claim 2, characterized in that the polymer matrix contains one or more polymers which are water-soluble and/or swellable in aqueous media, said polymers preferably being selected from the group comprising starch and starch derivatives, dextran, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose or propyl cellulose, polyacrylic acid, polyacrylates, polyvinyl pyrrolidones, polyethylene oxide polymers, polyacrylamides, polyethylene glycol, gelatine, collagen, alginates, pectins, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar-agar, agarose, carrageenan, and natural gums, the polymer portion preferably being 5 to 95%-wt, especially preferably 15 to 75%-wt.

4. Administration form according to any one of the preceding claims, characterized in that it contains the cannabis extract or the cannabis oil in an amount of 0.5 to 50%-wt, preferably in an amount of 1 to 30%-wt.

5. Administration form according to any one of the preceding claims, characterized in that it contains one or more substances from the group of the flavourings, odorous substances and aromatics, especially from the group com-

prising menthol, eucalyptol, limonene, phenyl ethanol, camphene, pinene, seasoning aromatics such as n-butyl phthalide or cineol, as well as eucalyptus oil and thyme oil, methyl salicylate, turpentine oil, camomile oil, ethyl vanillin, 6-methyl coumarin, citronellol, and acetic acid n-butyl ester.

6. Administration form according to any one of the preceding claims, characterized in that the layer thickness thereof is 0.01 to 2 mm, preferably 0.05 to 0.5 mm.

7. Administration form according to any one of the preceding claims, characterized in that it contains one or more inactive ingredients from the group of the fillers, colourants, emulsifiers, plasticizers, sweeteners, preservatives, pH regulators, permeation-enhancing substances, and antioxidants.

8. Administration form according to any one of the preceding claims, characterized in that it has a multilayer structure, with at least one layer having an active agent content.

9. Use of a cannabis extract or of a cannabis oil for the production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of:

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic

transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsia; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

10. Use of a cannaboid active agent, preferably from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromen, for the production of a film-shaped, mucoadhesive administration form for the therapeutic treatment of:

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsia; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

11. Use according claim 9 or 10, characterized in that the administration form is an administration form according to any one of claims 2 to 8.

12. Use according to any one of claims 9 to 11, characterized in that the treatment is effected by application of

the administration form to the oral mucosa, especially sublingually or buccally.

13. Use according to any one of claims 1 to 8 for therapeutic treatment, especially for the treatment of:

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsia; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

14. Use of a film-shaped, mucoadhesive administration form containing a cannaboid active agent, preferably selected from the group consisting of tetrahydrocannabinol, cannabinol, cannabidiol and cannabichromen, for therapeutic treatment, especially for the treatment of:

conditions of pain in cases of carcinosis and as a result of chemotherapy; conditions of pain and "wasting" syndrome in connection with AIDS; nausea and vomiting, especially nausea and vomiting as side effects of a chemotherapy as well as in connection with AIDS or hepatitis; neuropathic pain; anorexia or cachexia, especially in connection with AIDS or carcinosis in the advanced stages; paralytic symptoms in connection with multiple sclerosis or traumatic

transverse lesions; dystonic motor disturbance; bronchial asthma; epileptic attacks or generalized epilepsia; withdrawal symptoms in connection with alcohol dependence, benzodiazepine dependence and opiate dependence; Parkinson's disease; dementia, especially Alzheimer's disease; arthritis; glaucoma; migraine; dysmenorrhoea.

15. Use according to claim 14, characterized in that the administration form is an administration form according to any one of claims 2 to 8.

16. Use according to any one of claims 13 to 15, characterized in that the application is carried out on the oral mucosa, especially sublingually or buccally.